Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome

Journal of Clinical Oncology, 05/02/2012

Deferasirox reduces serum ferritin and Labile plasma iron (LPI) in transfusion–dependent patients with MDS. A subset of patients had an improvement in hematologic and hepatic parameters.

Print Article Summary Cat 2 CME Report